Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00784134 · ClinicalTrials.gov registry record · Phase 3
Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III
A Phase 3 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT00784134: Completed Phase 3 study, sponsored by Johns Hopkins University.
NCT00784134 is a Phase 3 study that has completed, run by Johns Hopkins University. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00784134, a Phase 3 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
The overall objective of this Phase III clinical trial is to obtain information from a population of 500 ICH subjects with intraventricular hemorrhage (IVH), representative of current clinical practice and national demographics of ICH regarding the benefit (or lack thereof) of IVH clot removal on subject function as measured by modified Rankin Scale (mRS). This application requests funding for five years to initiate a Phase III randomized clinical trial (RCT) testing the benefit of clot removal for intraventricular hemorrhage. The investigators propose to compare extraventricular drainage (EVD) use plus recombinant tissue plasminogen activator (rt-PA; Alteplase; Genentech, Inc., San Francisco, CA) with EVD+ placebo in the management and treatment of subjects with small intracerebral hemorrhage (ICH) and large intraventricular hemorrhage (IVH defined as ICH \< 30 cc and obstruction of the 3rd or 4th ventricles by intraventricular blood clot).
Interventions
- OTHER Normal saline
- DRUG Alteplase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2009-07 |
| Est. Completion | 2016-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00784134
The ClinicalTrials.gov registry entry for NCT00784134 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT00784134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00784134 about?
NCT00784134 is a clinical study titled "Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III". The overall objective of this Phase III clinical trial is to obtain information from a population of 500 ICH subjects with intraventricular hemorrhage (IVH), representative of current clinical practice and national demographics of ICH regarding the benefit (or lack thereof) of IVH clot removal on su...
What is the current status of trial NCT00784134?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2009-07. Estimated completion is 2016-01.
What interventions are being tested in trial NCT00784134?
The interventions under investigation include: Normal saline (OTHER), Alteplase (DRUG).
Who is sponsoring clinical trial NCT00784134?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.